Nanovibronix (NASDAQ:FEED – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($6.88) earnings per share for the quarter, FiscalAI reports. Nanovibronix had a negative net margin of 712.30% and a negative return on equity of 47.82%. The company had revenue of $0.65 million during the quarter.
Nanovibronix Stock Down 7.8%
Shares of Nanovibronix stock traded down $0.09 during trading on Monday, reaching $1.01. 268,340 shares of the company were exchanged, compared to its average volume of 8,416,940. Nanovibronix has a twelve month low of $0.99 and a twelve month high of $17.40. The business’s 50-day simple moving average is $1.63. The stock has a market cap of $3.74 million, a price-to-earnings ratio of -0.02 and a beta of 1.59.
Wall Street Analyst Weigh In
A number of research firms have commented on FEED. Weiss Ratings reissued a “sell (e+)” rating on shares of Nanovibronix in a research note on Friday, April 24th. Wall Street Zen upgraded Nanovibronix from a “strong sell” rating to a “sell” rating in a research note on Tuesday, April 28th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Sell”.
About Nanovibronix
Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company’s product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.
The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies.
Read More
- Five stocks we like better than Nanovibronix
- Why Applied Optoelectronics Stock May Be Near a Turning Point
- From High-Yield to High-Growth: 3 Stocks Boosting Dividends
- Is Everspin Technologies the Next AI Edge Breakout?
- 5 Robotics Stocks to Watch as Physical AI Builds Momentum
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
